

ESPEN guideline clinical nutrition in neurology clinical Nutrition 37 (2018) 354e396 Pasquinelli S, Solaro C.

Nutritional assessment and malnutrition in multiple sclerosis. Neurol Sci 2008 Dec 16;29(Suppl 4(S4)):S367e9. Poorjavand M, Derakhshandeh F, Etemadifar M, Soleymani B, Minagar A, Maghzi A-H.

Oropharyngeal dysphagia in multiple sclerosis. Mult Scler 2010 Mar 1;16(3):362e5. Schwarz S, Leweling H.

Multiple sclerosis and nutrition. Mult Scler 2005 Feb;11(1):24e32. Habek M, Hojsak I, Brinar VV.

Nutrition in multiple sclerosis. Clin Neurol Neurosurg 2010 Sep;112(7):616e20. Swank RL.

Multiple sclerosis; a correlation of its incidence with dietary fat. Am J Med Sci 1950 Oct;220(4):421e30. Swank RL, Lerstad O, Strøm A, Backer J.

Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N Engl J Med 1952 May 8;246(19):722e8. Ruxton CHS, Calder PC, Reed SC, Simpson MJA.

The impact of long-chain n-3 polyunsaturated fatty acids on human health. Nutr Res Rev 2005 Jun 10;18(01):113. Hoare S, Lithander F, van der Mei I, Ponsonby A-L, Lucas R, Ausimmune Investigator Group C, et al.

Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: results from the Ausimmune Study. Mult Scler 2016 Jun 1;22(7):884e92. Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, et al.

ω 3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol 2012 Aug 1;69(8): 1044e51. Schmitz K, Barthelmes J, Stolz L, Beyer S, Diehl O, Tegeder I.

Disease modifying nutraceuticals for multiple sclerosis. Pharmacol Ther 2015 Apr;148: 85e113. Pozuelo-Moyano B, Benito-Leon J.

Diet and multiple sclerosis. Rev Neurol 2014 May 16;58(10):455e64. van der Mei IA, Ponsonby AL, Blizzard L, Dwyer T.

Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 2001 Aug;20(3):168e74. Staples J, Ponsonby A-L, Lim L.

Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. BMJ 2010 Apr 29;340:c1640. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A.

Serum 25 hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006 Dec 20;296(23):2832. Compston A, Coles A.

Multiple sclerosis. Lancet 2008 Oct 25;372(9648): 1502e17. Munger KL, Ascherio A.

Prevention and treatment of MS: studying the effects of vitamin D. Mult Scler J 2011 Dec 1;17(12):1405e11. Wade DT, Young CA, Chaudhuri KR, Davidson DLW.

A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002 Sep;73(3):246e9. Lange LS, Shiner M, Bateson MC, Hopwood D, MacGillivray JB, Lange LS, et al.

Jejunal morphology in multiple sclerosis. Lancet (London, England) 1979 Jun 16;1(8129):1300e1. Hadjivassiliou M, Gibson A, Davies-Jones GA, Lobo AJ, Stephenson TJ, Milford-Ward A.

Does cryptic gluten sensitivity play a part in neurological illness? Lancet (London, England) 1996 Feb 10;347(8998):369e71. Hunter AL, Rees BW, Jones LT.

Gluten antibodies in patients with multiple sclerosis. Hum Nutr Appl Nutr 1984 Apr;38(2):142e3. Hewson DC.

Is there a role for gluten-free diets in multiple sclerosis? Hum Nutr Appl Nutr 1984 Dec;38(6):417e20. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF.

Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000 Sep;72(3):690e3. Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J, et al.

The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 2004 Mar;89(3): 1196e9. Munger KL, Chitnis T, Ascherio A.

Body size and risk of MS in two cohorts of US women. Neurology 2009 Nov 10;73(19):1543e50. Simon KC, Munger KL, Ascherio A.

XVI European Charcot Foundation lecture: nutrition and environment: can MS be prevented? J Neurol Sci 2011 Dec 15;311(1e2):1e8. Hedstrom AK, Olsson T, Alfredsson L.

High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler J 2012 Sep 1;18(9):1334e6. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, et al.

Vitamin D intake and incidence of multiple sclerosis. Neurology 2004 Jan 13;62(1):60e5. Ascherio A, Munger KL, White R, Kœchert K, Simon KC, Polman CH, et al.

Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014 Mar 1;71(3):306e14. Ascherio A, Munger KL, Simon KC.

Vitamin D and multiple sclerosis. Lancet Neurol 2010 Jun;9(6):599e612. Kampman MT, Steffensen LH.

The role of vitamin D in multiple sclerosis. J Photochem Photobiol B 2010 Nov 3;101(2):137e41 Multiple Sclerosis.

Management of multiple sclerosis in primary and secondary care- PubMed- NCBI [internet]. London: National Institute for Health and Care Excellence (UK); London; 2014 [cited 2017 Jan 1]. .

Vitamin D for the treatment or prevention of multiple sclerosis: a review of the clinical effectiveness. Canadian Agency for Drugs and Technologies in Health; 2016. Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H.

Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012;2012:452541. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch H-M, Cheung R, et al. **A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis.** Neurology 2010 Jun 8;74(23):1852e9. Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L.

Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double blind randomised controlled trial. Mult Scler 2012 Aug 1;18(8):1144e51. Soilu-Hänninen M, Aivo J, Lindström B-M, Elovaara I, Sumelahti M-L, Färkkilä M, et al.

A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon b-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012 May;83(5):565e71. Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, et al.

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011 Oct 25;77(17):1611e8. Golan D, Halhal B, Glass-Marmor L, Staun-Ram E, Rozenberg O, Lavi I, et al.

Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol 2013 Jun 14;13(1):60. Autier P, Boniol M, Pizot C, Mullie P.

Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2014 Jan;2(1):76e89. James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV.

The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler 2013 Oct 1;19(12):1571e9. Mehta LR, Dworkin RH, Schwid SR.

Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nat Clin Pract Neurol 2009 Feb;5(2):82e92. Dworkin RH, Bates D, Millar JH, Paty DW.

Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials. Neurology 1984 Nov;34(11): 1441e5. Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G.

Dietary interventions for multiple sclerosis. In: Farinotti M, editor. Cochrane data base of systematic reviews. Chichester, UK: John Wiley & Sons, Ltd; 2012. CD004192. Bates D, Cartledge NE, French JM, Jackson MJ, Nightingale S, Shaw DA, et al.

A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 1989 Jan;52(1):18e22. Payne A.

Nutrition and diet in the clinical management of multiple sclerosis. J Hum Nutr Diet 2001 Oct;14(5):349e57. Sorgun MH, Yucesan C, Tegin C.

Is malnutrition a problem for multiple sclerosis patients? J Clin Neurosci 2014 Sep;21(9):1603e5. Payne C, Wiffen PJ, Martin S.

Interventions for fatigue and weight loss in adults with advanced progressive illness. In: Payne C, editor. Cochrane database syst rev, vol. 1; 2012 Jan 18. CD008427. Baldwin C, Weekes CE.

Dietary advice with or without oral nutritional supplements for disease-related malnutrition in adults. In: Baldwin C, editor. Cochrane database of systematic reviews. Chichester, UK: John Wiley & Sons, Ltd; 2011. CD002008. Baldwin C, Weekes CE.

Dietary advice for illness-related malnutrition in adults. In: Baldwin C, editor. Cochrane database syst rev, vol. 23;(1); 2008 Jan. CD002008. Baldwin C, Weekes CE.

Dietary counselling with or without oral nutritional supplements in the management of malnourished patients: a systematic review and meta-analysis of randomised controlled trials. J Hum Nutr Diet 2012 Oct;25(5):411e26. Cawood AL, Elia M, Stratton RJ.

Systematic review and meta-analysis of the effects of high protein oral nutritional supplements. Ageing Res Rev 2012 Apr;11(2):278e96. Elia M, Normand C, Laviano A, Norman K.

Asystematic review of the cost and cost effectiveness of using standard oral nutritional supplements in community and care home settings. Clin Nutr 2016 Feb;35(1):125e37. Stratton RJ, Elia M.

Encouraging appropriate, evidence-based use of oral nutritional supplements. Proc Nutr Soc 2010 Nov 10;69(4):477e87. Chruzander C, Johansson S, Gottberg K, Einarsson U, Fredrikson S, Holmqvist LW, et al.

A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: changes in disability and the value of different factors in predicting disability and mortality. J Neurol Sci 2013 Sep 15;332(1e2):121e7. Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, et al.

Relative mortality and survival in multiple sclerosis: findings from British Columbia. Can J Neurol Neurosurg Psychiatry 2012 Jan;83(1):61e6. Scafari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC.

Mortality in patients with multiple sclerosis. Neurology 2013 Jul 9;81(2):184e92. Rodríguez-Antigüedad Zarranz A, Mendibe Bilbao M, Larena Gonzalez C, Audicana C.

Mortality and cause of death in multiple sclerosis: findings from a prospective population-based cohort in Bizkaia, Basque Country, Spain. Neuroepidemiology 2014;42(4):219e25. De Pauw A, De Jaeger E, D'hooghe B, Carton H.

Dysphagia in multiple sclerosis. Clin Neurol Neurosurg 2002 Sep;104(4):345e51. Tassorelli C, Bergamaschi R, Buscone S, Bartolo M, Furnari A, Crivelli P, et al.

Dysphagia in multiple sclerosis: from pathogenesis to diagnosis. Neurol Sci 2008 Dec 16;29(S4):360e3. Abraham Suzanne, Scheinberg LabeC, Smith Charles R, LaRocca Nicholas G.

Neurologic impairment and disability status in outpatients with multiple sclerosis reporting dysphagia symptomatology. J Neuro Rehab 1997;11(1): 7e13. Bergamaschi R, Crivelli P, Rezzani C, Patti F, Solaro C, Rossi P, et al.

The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. J Neurol Sci 2008 Jun 15;269(1e2):49e53. Bergamaschi R, Rezzani C, Minguzzi S, Amato MP, Patti F, Marrosu MG, et al.

Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. Funct Neurol 2009;24(3):159e62. Solaro C, Rezzani C, Trabucco E, Amato MP, Zipoli V, Portaccio E, et al.

Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire). J Neurol Sci 2013 Aug 15;331(1e2):94e7. Alfonsi E, Bergamaschi R, Cosentino G, Ponzio M, Montomoli C, RD. Elettrophysiological patterns of oropharyngeal swallowing in multiple sclerosis. Clin Neurophysiol 2013;124:1638e45. Levinthal DJ, Rahman A, Nusrat S, O'Leary M, Heyman R, Bielefeldt K, et al.

Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int 2013;2013:319201. Thomas FJ, Wiles CM.

Dysphagia and nutritional status in multiple sclerosis. J Neurol 1999 Aug;246(8):677e82. Fernandes AMF, Duprat A de C, Eckley CA, da Silva L, Ferreira RB, Tilbery CP.

Oropharyngeal dysphagia in patients with multiple sclerosis: do the disease classification scales reflect dysphagia severity? Braz J Otorhinolaryngol 2013 Aug;79(4):460e5. Wiesner W, Wetzel SG, Kappos L, Hoshi MM, Witte U, Radue EW, et al.

Swallowing abnormalities in multiple sclerosis: correlation between video fluoroscopy and subjective symptoms. Eur Radiol 2002 Apr 5;12(4):789e92. Terre-Boliart R, Orient-Lopez F, Guevara-Espinosa D, Ramon-Rona S, Bernabeu-Guitart M, Clave-Civit P.

Oropharyngeal dysphagia in patients with multiple sclerosis. Rev Neurol 2004;39(8):707e10. Beckmann Y, Gürgör N, Çakır A, Arıcı S, İncesu TK, Seçil Y, et al.

Electro physiological evaluation of dysphagia in the mild or moderate patients with multiple sclerosis: a concept of subclinical dysphagia. Dysphagia 2015 Jun 17;30(3):296e303. Giusti A, Giambuzzi M.

Management of dysphagia in patients affected by multiple sclerosis: state of the art. Neurol Sci 2008 Dec 16;29(Suppl 4(S4)): S364e6. Prosiegel M, Schelling A, Wagner-Sonntag E.

Dysphagia and multiple sclerosis. Int MS J 2004 Apr;11(1):22e31. Kesselring J, Beer S.

Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 2005 Oct;4(10):643e52. Leder SB, Judson BL, Sliwinski E, Madson L.

Promoting safe swallowing when puree is swallowed without aspiration but thin liquid is aspirated: nectar is enough. Dysphagia 2013 Mar 27;28(1):58e62. [325] de Luis DA, Izaola O, de la Fuente B, Muñoz-Calero P, Franco-Lopez A.

Neurodegenerative diseases; nutritional aspects. Nutr Hosp 2015 Aug 1;32(2):946e51. Cristian D, Poalelungi A, Anghel A, Burcos T, Grigore R, Bertescu S, et al.

Prophylactic percutaneous endoscopic gastrostomy (PEG)- the importance of nutritional support in patients with head and neck cancers (HNCs) or neurogenic dysphagia (ND). Chir (Bucur) 2015;110(2):129e36. Gencosmanoglu R.

Percutaneous endoscopic gastrostomy: a safe and effective bridge for enteral nutrition in neurological or non-neurological conditions. Neurocrit Care 2004;1(3):309e17. Zalar AE, Guedon C, Piskorz EL, Sanchez Basso A, Ducrotte P.

Percutaneous endoscopic gastrostomy in patients with neurological diseases. Results of a prospective multicenter and international study. Acta Gastroenterol Latin Am 2004;34(3):127e32.

The Role of Diet in Multiple Sclerosis: Mechanistic Connections and Current Evidence Katz SI. **Classification, diagnosis, and differential diagnosis of multiple sclerosis.** Curr Opin Neurol. 2015;28(3):193–205. Calabrese M.

Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol. 254(9):1212–20. Fisniku LK. **Gray matter atrophy is related to long-term disability in multiple sclerosis.** Ann Neurol. 64(3):247–54. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al.

Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86. Hedström AK.

Environmental factors and their interactions with risk genotypes in MS susceptibility. Curr Opin Neurol.

2016a;29(3):293–8. Olsson TT.

Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 13(1):

Munger KL. **Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.** JAMA. 296(23):2832–8. VanderMeil AF

.Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ (Clinical research ed).

327(7410) Hedström AK. Smoking is a major preventable risk factor for multiple sclerosis. Mult Scler. 2016b;22(8):1021–6 Thacker E LEL.

Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol. 59(3):499–503. Hedstrom AK,

Lima Bomfim I, Barcellos L, Gianfrancesco M, Schaefer C, Kockum I, et al.

Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology.

2014;82(10):865–72. Simpson S.

Sun exposure across the life course significantly modulates early multiple sclerosis clinical course. Front Neurol.

2018;9 Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ.

Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology. 2012;79(3):261–

6. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, et al.

Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol.

2012;72(2):234–40. VanderVorst de Vries RM. Smoking at time of CIS increases the risk of clinically definite multiple

sclerosis. J Neurol. 2018; Briggs FB. Smokers with MS have greater decrements in quality of life and disability than non-smokers. Mult Scler. 2017 Swank RL, Lerstad O, Strom A, Backer J.

Multiple sclerosis in rural Norway: its geographic and occupational incidence in relation to nutrition. N Engl J Med.

1952;246(19):722–8. Dendrou CA.

Immunopathology of multiple sclerosis. Nat Rev Immunology. 15(9):545–58. **Excellent review of multiple sclerosis**

pathophysiology. International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, et al.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature.

2011;476(7359):214–9. Sawcer S, Franklin RJ,

Ban M. Multiple sclerosis genetics. Lancet Neurol. 2014;13(7):700–9. Hemmer B

.Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 14(4):406–Rojas

Jl, Patrucco L, Miguez J, Besada C, Cristiano E.

Brain atrophy in radiologically isolated syndromes. J Neuroimaging. 2015;25(1):68–71. Fries MA.

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 10(4):225–38.

2014.37. **Excellent review of neurodegenerative aspect of multiple sclerosis.** Mao P, Reddy PH.

Is multiple sclerosis a mitochondrial disease? Mitochondrial Dysfunction. 2010;1802(1):66–79.

Goldschmidt T. **Remyelination capacity of the MS brain decreases with disease chronicity.** Neurology. 72(22):1914–21.

Kuhlmann T. **Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis.**

Brain (London, England : 1878). 131:1749–58. Stangel M.

Achievements and obstacles of remyelinating therapies in multiple sclerosis. Nat Rev Neurol. 13(12):742–54. Langer-

Gould A, Brara SM, Beaber BE, Koebnick

C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology.

2013;80(6):548–52. 158 Curr Nutr Rep (2018) 7:150–160 Munger KL, Bentzen J, Laursen B, Stenager E, Koch-Henriksen N, Sorensen TI, et al.

Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler (Houndmills, Basingstoke,

England). 2013;19(10):1323–9. Tetley P, Simpson S, Taylor B, Ponsonby AL, Lucas RM, Dwyer T, et al.

An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event. J Neurol Neurosurg Psychiatry. 2017;88(5):395–401. Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M,

Sobisek L, et al.

Serum lipid profile changes predict neurodegeneration in interferon-beta1a-treated multiple sclerosis patients. J Lipid

Res. 2017;58(2):403–11. Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, et al.

Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry. 2013;84(11):1186–91 Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J, et al.

Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation. 2011;8:127–2094-8-127 Altowaijri G. Dietary interventions and multiple sclerosis. Curr Neurol Neurosci Rep. 2017;17(3) Moss BP.

Wellness and the role of comorbidities in multiple sclerosis. Neurotherapeutics. 14(4):999–1017. Thorburn AN, Macia L, Mackay CR. **Diet, metabolites, and “western-lifestyle” inflammatory diseases.** Immunity. 2014;40(6):833–42 Moniri NH. **Free-fatty acid receptor-4 (GPR120): Cellular and molecular function and its role in metabolic disorders.** Biochem Pharmacol. 2016;110–111:1–15. Wirthgen E.

Kynurenic acid: the Janus-faced role of an immuno modulatory tryptophan metabolite and its link to pathological conditions. Front Immunol. 2017; McKenzie CI. **GPR43—a prototypic metabolite sensor linking metabolic and inflammatory diseases.** Trends Endocrinol Metab. 26(10):511–2. Tao R

Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 13(11):1299–307. Gutiérrez-Vázquez C.

Regulation of the immune response by the aryl hydrocarbon receptor. Immunity (Cambridge, Mass). 48(1): 19–33. Rothhammer V. **Environmental control of autoimmune inflammation in the central nervous system.** Curr Opin Immunol. 43:46. Rothhammer V.

Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med. 2016;22(6):586–97. **This study connects dietary tryptophan intake with effects inside the CNS mediated by the aryl hydrocarbon receptor.** Ochoa-Reparaz J, Mielcarz DW, Ditrio LE, Burroughs AR, Foureau DM, Haque-Begum S, et al.

Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol (Baltimore, Md: 1950). 2009;183(10):6041–This study first established the importance of gut microbiota in an animal model of MS. Ochoa-Reparaz J, Mielcarz DW, Wang Y, Begum-Haque S, Dasgupta S, Kasper DL, et al.

A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol. 2010;3(5):487–95. Berer K.

Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci. 2017;11233. Cekanaviciute E. Proc Natl Acad Sci. 2017;11235 **This study comprises the largest cohort to date studying the gut microbiota of untreated MS patients compared to healthy controls.** Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, et al. **Alterations of the human gut microbiome in multiple sclerosis.** Nat Commun. 2016;7:12015. Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, et al.

Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV clusters. PloS One. 2015;10(9): e0137429. Chen JJ.

Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 6(1):28484. Libbey JE. **Variations in diet cause alterations in microbiota and metabolites that follow changes in disease severity in a multiple sclerosis model.** Benefic Microbes:1–20 Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, et al.

Peripheral education of the immune system by colonic commensal microbiota. Nature. 2011;478(7368):250–4 Akira S, Uematsu S, Takeuchi O.

Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801. 54. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, et al. **Factors influencing the composition of the intestinal microbiota in early infancy.** Pediatrics. 2006;118(2):511–21. Dethlefsen L, Huse S, Sogin ML, Relman DA.

The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280. Dethlefsen L, Relman DA. **Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation.** Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4554–61 Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al.

Linking long-term dietary patterns with gut microbial enterotypes. Science (New York, NY). 2011;334(6052):105–8. This study establishes the important influence of dietary habits on gut microbial composition. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, et al.

The long-term stability of the human gut microbiota. Science (New York, NY). 2013;341(6141):1237439. Ruiz-Núñez B. **The relation of saturated fatty acids with low-grade inflammation and cardiovascular disease.** J Nutr Biochem. 2016;36:1–20. Curr Nutr Rep (2018) 7:150–160 159 Huang S.

Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. *J Lipid Res.* 53(9):2002–13.

Mani V. Dietary oil composition differentially modulates intestinal endotoxin transport and postprandial endotoxemia. *Nutr Metabol.* 10(1)

Timmermans S. High fat diet exacerbates neuroinflammation in an animal model of multiple sclerosis by activation of the renin-angiotensin system. *J Neuroimmune Pharmacol.* 9(2):209–17. Haghighi A, Jorg S, Duscha A, Berg J, Manzel A, Waschbisch A, et al.

Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. *Immunity.* 2015;43(4):817–29. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al.

Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature.* 2013;504(7480):446–50. Swank RL.

Multiple sclerosis; a correlation of its incidence with dietary fat. *Am J Med Sci.* 220(4):421–30.

Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. *Lancet.* 1990;336(8706):37–9. This paper reports long-term results of Swank's interventional study of a low-saturated fat diet in MS. Swank RL.

Review of MS patient survival on a Swank low saturated fat diet. *Nutrition* (Burbank, Los Angeles County, Calif). 19(2):161–2. Azary S.

Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 89(1):28–33. Prospective study in pediatric MS suggesting a negative impact of saturated fats and a benefit for vegetable intake. von Geldern G, Mowry EM.

The influence of nutritional factors on the prognosis of multiple sclerosis. *Nat Rev Neurol.* 2012;8(12):678–89. Unoda K, Doi Y, Nakajima H, Yamane K, Hosokawa T, Ishida S, et al.

Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis. *J Neuroimmunol.* 2013;256(1–2):7–12. Salvati S, Di Biase A, Attorri L, Di Benedetto R, Sanchez M, Lorenzini L, et al.

Ethyl-eicosapentaenoic acid ameliorates the clinical course of experimental allergic encephalomyelitis induced in dark agouti rats. *J Nutr Biochem.* 2013;24(9):1645–54. Di Biase A, Salvati S, Di Benedetto R, Attorri L, Martinelli A, Malchiodi F.

Eicosapentaenoic acid pre-treatment reduces biochemical changes induced in total brain and myelin of weanling Wistar rats by cuprizone feeding.

Prostaglandins *Leukot Essent Fat Acids.* 2014;90(4):99–104. Torkildsen O, Brunborg LA, Thorsen F, Mork SJ, Stangel M, Myhr KM, et al.

Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. *Exp Neurol.* 2009;215(1):160–6. Zhang SM, Willett WC, Hernan MA, Olek MJ, Ascherio A.

Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. *Am J Epidemiol.* 2000;152(11):1056–64. Bjørnevik K.

Polyunsaturated fatty acids and the risk of multiple sclerosis. *Mult Scler.* 23(14):1830–8. Baarnhielm M, Olsson T, Alfredsson L.

Fatty fish intake is associated with decreased occurrence of multiple sclerosis. *Mult Scler* (Houndmills, Basingstoke, England). 2014;20(6):726–32. Hoare S, Lithander F, van der Mei I, Ponsonby AL, Lucas R, Ausimmune Investigator G.

Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: results from the Ausimmune Study. *Multiple sclerosis* (Houndmills, Basingstoke, England). 2015;Langer-Gould A, editor.

Fresh fish consumption is associated with a lower risk of multiple sclerosis independent of serum 25OHD levels. *Paris: ECTRIMS; 2017.* Bates D.

A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 52(1):18–22. Bates D.

Polyunsaturated fatty acids in treatment of acute relapsing multiple sclerosis. *Br Med J.* 2(6149):1390–1. Bates D.

Trial of polyunsaturated fatty acids in non-relapsing multiple sclerosis. *Br Med J.* 2(6092):932–3. Torkildsen O.

ω-3 Fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo controlled trial. *Arch Neurol* (Chicago). 2012;69(8):1044–51. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al.

Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. *Prostaglandins Leukot Essent Fat Acids.* 2005;73(5):397–404. Gu Y.

Dietary patterns in Alzheimer's disease and cognitive aging. *Curr Alzheimer Res.* 8(5):510–9. Gu YY.

Mediterranean diet and brain structure in a multiethnic elderly cohort. *Neurology.* 85(20):1744–51. This paper establishes the impact of Mediterranean diet adherence on structural imaging metrics associated with cognitive decline.

Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, et al.

Vitamin D intake and incidence of multiple sclerosis. *Neurology.* 2004;62(1):60–5. Ascherio A, Munger KL, White R, Kochert K, Simon KC, Polman CH, et al.

Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306–14.

Munger KL, Chitnis T, Frazier AL, Giovannucci E, Spiegelman D, Ascherio

A. Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J Neurol. 2011;258(3):479–85. Banwell B, Bar-Or A, Cheung R, Kennedy J, Krupp LB, Becker DJ, et al.

Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol. 2008;63(1):98–111. Winer S, Astsaturon I, Cheung RK, Schrade K, Gunaratnam L, Wood DD, et al.

T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice. J Immunol (Baltimore, Md: 1950). 2001;166(7):4751–6. Stefferl A, Schubart A, Storch M, Amini A, Mather I, Lassmann H, et al. **Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis.** J Immunol (Baltimore, Md: 1950). 2000;165(5):2859–65. Guggenmos J, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, et al.

Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. J Immunol (Baltimore, Md: 1950). 2004;172(1): 661–8. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, et al.

Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL10^{-/-} mice. Nature. 2012;487(7405):104–8. Hadjickiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, van der Meer DM.

The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis. Curr Nutr Rep (2018) 7:150–160 with multiple sclerosis. Nutr Neurosci. 2014; Registry-based study suggesting links between various dietary factors and MS severity. Fitzgerald KC.

Diet quality is associated with disability and symptom severity in multiple sclerosis. Neurology. 90(1):e1–e11. Registry based study suggesting links between various dietary factors and MS severity. Aresella M.

Immunological and clinical effect of diet modulation of the gut microbiome in multiple sclerosis patients: a pilot study. Front Immunol. 2017;8:1010. MAR.

Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3(10):858–76. Xue Z.

Mechanisms and therapeutic prospects of polyphenols as modulators of the aryl hydrocarbon receptor. Food Funct. 8(4): 1414–37. McKenzie C. The nutrition-gut microbiome-physiology axis and allergic diseases. Immunol Rev. 2017;278(1):277–95. Spagnuolo C.

Anti-inflammatory effects of flavonoids in neurodegenerative disorders. Eur J Med Chem. Excellent review of the anti-inflammatory properties of flavonoids and their role in neurodegeneration. Haghmorad D.

Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis. J Neuroimmunol. 2017;302:23–33. Wang J. **Dietary naringenin supplementation attenuates experimental autoimmune encephalomyelitis by modulating autoimmune inflammatory responses in mice.** J Nutr Biochem. 54:130–9. Hashimoto M.

The flavonoid Baicalein attenuates cuprizone induced demyelination via suppression of neuroinflammation. Brain Res Bull. 135:47–52. Zhang Q.

Myricetin alleviates cuprizone-induced behavioral dysfunction and demyelination in mice by Nrf2 pathway. Food Funct. 7(10):4332–42. Skaper SD.

Co-ultramicrosized palmitoylethanolamide/luteolin facilitates the development of differentiating and undifferentiated rat oligodendrocyte progenitor cells. Mol Neurobiol. 55(1):103–14. Zhang Y.

Icariin enhances remyelination process after acute demyelination induced by cuprizone exposure. Brain Res Bull. 2017;130:180–7. Joseph JA.

Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. J Neurosci. 19(18):8114–21. Miller MG.

Dietary blueberry improves cognition among older adults in a randomized, double-blind, placebo-controlled trial. Eur J Nutr. 57(3):1169–80. Xin J, Feinstein DL, Hejna MJ, Lorens SA, McGuire SO. Beneficial effects of blueberries in experimental autoimmune encephalomyelitis. J Agric Food Chem. 2012;60(23):5743–8. Wu C, Yosef N, Thalhammer T, Zhu C, Xiao S, Kishi Y, et al.

Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature. 2013;496(7446):513–7. Kleinewietfeld M, Manzel A, Titzel J, Kvakarn H, Yosef N, Linker RA, et al.

Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature. 2013;496(7446): 518–22. Farez MF, Fiol MP, Gaitan MI, Quintana FJ, Correale J.

Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):26–31. McDonald J.

A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. Mult Scler Relat Disord. 6:87–92. Nourbakhsh B.

Dietary salt intake and time to relapse in paediatric multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(12):1350–3. Fitzgerald KC, et al. Ann Neurol. 82(1):20–9. Anderson RM.

Caloric restriction research: new perspectives on the biology of aging. J Gerontol A Biol Sci Med Sci. 73(1):1–3. Esquifino AI. Experimental allergic encephalomyelitis in male Lewis rats subjected to calorie restriction. J Physiol Biochem. 60(4):245–52. Esquifino AI. Immune response after experimental allergic encephalomyelitis in rats subjected to calorie restriction. J Neuroinflamm. 4(1) Piccio L. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. J Leukoc Biol. 84(4):940–8. Kafami L.

Intermittent feeding attenuates clinical course of experimental autoimmune encephalomyelitis in C57BL/6 mice. Avicenna J Med Biotechnol. 2(1):47–52. Choi IY.

A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms. Cell Rep (Cambridge). 2016;15(10):2136–46. Yadav V, Marracci G, Kim E, Spain R, Cameron M, Overs S, et al.

Effects of a low fat plant based diet in multiple sclerosis (MS): results of a 1-year long randomized controlled (RC) study (P6.152). Neurology. 2014;82(10 Supplement):P6.152–P6. Bisht B, Darling WG, Grossmann RE, Shivapour ET, Lutgendorf SK, Snetselaar LG, et al.

A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue. J Altern Complement Med (New York, NY). 2014;20(5):347–55. Gardener S. **Adherence to a Mediterranean diet and Alzheimer's disease risk in an Australian population.** Transl Psychiatry. 2(10): e164.

The Role of Diet in Multiple Sclerosis Onset: A Prospective Study Using UK Biobank Naseri, A.; Nasiri, E.; Sahraian, M.A.; Daneshvar, S.; Talebi, M.

Clinical Features of Late-Onset Multiple Sclerosis: A Systematic Review and Meta-Analysis. Mult. Scler. Relat. Disord. 2021, 50, 102816. Ghasemi, N.; Razavi, S.; Nikzad, E.

Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell J. 2017, Pitt, D.; Lo, C.H.; Gauthier, S.A.; Hickman, R.A.; Longbrake, E.; Airas, L.M.; Mao-Draayer, Y.; Riley, C.; De Jager, P.L.; Wesley, S.; et al. **Toward Precision Phenotyping of Multiple Sclerosis.** Neurol. Neuroimmunol. Neuroinflamm. 2022, 9, e200025. Steinman, L.

Multiple Sclerosis: A Two-Stage Disease. Nat. Immunol. 2001, 2, 762–764. **Multiple Sclerosis: Prevalence, Incidence and Smoking Status—Data Briefing—GOV.UK.** Available online: [incidence-and-smoking-status-data-briefing](https://www.gov.uk/government/data-and-data-set-releases/available-data-sets-and-reports/multiple-sclerosis-prevalence-incidence-and-smoking-status-data-briefing) Barbero Mazzucca, C.; Cappellano, G.; Chiocchetti,

Nutrition, Immunity and Aging: Current Scenario and Future Perspectives in Neurodegenerative Diseases. CNS Neurol. Disord. Drug Targets 2023, 23, 573–587. [D'Mello, C.; Swain, M.G. **Liver-Brain Inflammation Axis.** Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301, 749–761. [Veronese, N.; Yang, L.; Piccio, L.; Smith, L.; Firth, J.; Marx, W.; Giannelli, G.; Caruso, M.G.; Cisternino, A.M.; Notarnicola, M.; et al.

Adherence to a Healthy Lifestyle and Multiple Sclerosis: A Case–Control Study from the UK Biobank. Nutr. Neurosci. 2020, 25, 1231–1239. Guillet, C.; Rastmanesh, R.; Ruggieri, S.; De Giglio, L.; Felicetti, F.; Tommasin, S.; Petracca, M.; Gurreri, F.; Ianniello, A.; Nistri, R.; et al.

Eating Hubs in Multiple Sclerosis: Exploring the Relationship Between Mediterranean Diet and Disability Status in Italy. Front. Nutr. 2022, 1, 882426. [Coe, S.; Tektonidis, T.G.; Coverdale, C.; Penny, S.; Collett, J.; Chu, B.T.Y.; Izadi, H.; Middleton, R.; Dawes, H. **A Cross Sectional Assessment of Nutrient Intake and the Association of the Inflammatory Properties of Nutrients and Foods with Symptom Severity in a Large Cohort from the UK Multiple Sclerosis Registry.** Nutr. Res. 2021, 85, 31–39. Fitzgerald, K.C.; Tyry, T.; Salter, A.; Cofield, S.S.; Cutter, G.; Fox, R.; Marrie, R.A. **Diet Quality Is Associated with Disability and Symptom Severity in Multiple Sclerosis.** Neurology 2018, 90, E1–E11. Hadgkiss, E.J.; Jelinek, G.A.; Weiland, T.J.; Pereira, N.G.; Marck, C.H.; van der Meer, D.M.

The Association of Diet with Quality of Life, Disability, and Relapse Rate in an International Sample of People with Multiple Sclerosis. Nutr. Neurosci. 2015, 18, 125–Bayat, P.; Farshchi, M.; Yousefian, M.; Mahmoudi, M.; Yazdian-Robati, R. **Flavonoids, the Compounds with Anti-Inflammatory and Immunomodulatory Properties, as Promising Tools in Multiple Sclerosis (MS) Therapy: A Systematic Review of Preclinical Evidence.** Int. Immunopharmacol. 2021, 95, 107562. Rezaeizadeh, H.; Mohammadpour, Z.; Bitarafan, S.; Harirchian, M.H.; Ghadimi, M.; Homayon, I.A.

Dietary Fish Intake and the Risk of Multiple Sclerosis: A Systematic Review and Meta-Analysis of Observational Studies. Nutr. Neurosci. 2022, 25, 681–Bäårnhielm, M.; Olsson, T.; Alfredsson, L.

Fatty Fish Intake Is Associated with Decreased Occurrence of Multiple Sclerosis. Mult. Scler. 2014, 20, 726–732 Hedström, A.K.; Olsson, T.; Kockum, I.; Hillert, J.; Alfredsson, L.

Low Fish Consumption Is Associated with a Small Increased Risk of MS. *Neurol. (R) Neuroimmunol. Neuroinflamm.* 2020, 7, e717 Ascherio, A.; Munger, K.L.; Simon, K.C.

Vitamin D and Multiple Sclerosis. *Lancet Neurol.* 2010, 9, 599–612. Munger, K.L.; Chitnis, T.; Frazier, A.L.; Giovannucci, E.; Spiegelman, D.; Ascherio, A.

Dietary Intake of Vitamin D during Adolescence and Risk of Multiple Sclerosis. *J. Neurol.* 2011, 258, 479–485.

Banwell, B.; Bar-Or, A.; Cheung, R.; Kennedy, J.; Krupp, L.B.; Becker, D.J.; Dosch, H.M. **Abnormal T-Cell Reactivities in Childhood Inflammatory Demyelinating Disease and Type 1 Diabetes.** *Ann. Neurol.* 2008, 63, 98–111. Sharifi, M.H.;

Keshani, P.; Salehi, A.; Jaladat, A.M.; Mirzaei, Z.; Nikseresht, A. **Association between Multiple Sclerosis and Dietary Patterns Based on the Traditional Concept of Food Nature: A Case-Control Study in Iran.** *BMC Neurol.* 2021, Katz Sand, I.

The Role of Diet in Multiple Sclerosis: Mechanistic Connections and Current Evidence. *Curr. Nutr. Rep.* 2018, 7, Mazzucca, C.B.; Scotti, L.; Cappellano, G.; Barone-Adesi, F.; Chiocchetti,

Nutrition and Rheumatoid Arthritis Onset: A Prospective Analysis Using the UK Biobank. *Nutrients* 2022, 14, 1554.

Nishanth, K.; Tariq, E.; Nzvere, F.P.; Miqdad, M.; Cancarevic, I. **Role of Smoking in the Pathogenesis of Multiple Sclerosis: A Review Article.** *Cureus* 2020, 12, e9564] Manouchehrinia, A.; Huang, J.; Hillert, J.; Alfredsson, L.; Olsson, T.; Kockum, I.; Constantinescu, C.S. Smoking

Attributable Risk in Multiple Sclerosis. *Front. Immunol.* 2022, 13, 845. Ascherio, A.; Munger, K.L. **Environmental Risk Factors for Multiple Sclerosis.** Part II: Noninfectious Factors. *Ann. Neurol.* 2007, Maghzi, A.H.; Etemadifar, M.; Heshmat-Ghahdarijani, K.; Moradi, V.; Nonahal, S.; Ghorbani, A.; Minagar, A. Cigarette Smoking and **the Risk of Multiple Sclerosis: A Sibling Case-Control Study in Isfahan, Iran.** *Neuroepidemiology* 2011, 37, 238–242. Wingerchuk, D.M. Smoking: **Effects on Multiple Sclerosis Susceptibility and Disease Progression.** *Ther. Adv. Neurol. Disord.* 2012, 5, 13–22 Olsson, T.; Barcellos, L.F.; Alfredsson, L

Interactions between Genetic, Lifestyle and Environmental Risk Factors for Multiple Sclerosis. *Nat. Rev. Neurol.* 2017, 13, 26–36.] Gianfrancesco, M.A.; Barcellos, L.F.

Obesity and Multiple Sclerosis Susceptibility: A Review. *J. Neurol. Neuromed.* 2016, 1, 1. Wesnes, K.; Myhr, K.M.; Riise, T.; Cortese, M.; Pugliatti, M.; Boström, I.; Landtblom, A.M.; Wolfson, C.; Bjørnevik, K. **Physical Activity Is Associated with a Decreased Multiple Sclerosis Risk: The EnvIMS Study.** *Mult. Scler.* 2018, 24, 150–157. [Dorans, K.S.; Massa, J.; Chitnis, T.; Ascherio, A.; Munger, K.L. Physical Activity and the

Incidence of Multiple Sclerosis. *Neurology* 2016, 87, 1770. **The role of diet in multiple sclerosis: A review** Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. University of British Columbia MS Clinic Neurologists. **Early onset multiple sclerosis: a longitudinal study.** *Neurology* 2002;59(7):1006–10. Alroughani R, Akhtar S, Ahmed S, Behbehani R, Al-Hashel J. Is time to reach EDSS 6.0 faster in patients with late-onset versus young-onset multiple sclerosis? *PLoS One* 2016;11(11): e0165846. EbersGC.

Environmental factors and multiple sclerosis. *Lancet Neurol* 2008;7(3):268–77. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al.

Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology* 2014;83(3):278–86. Masullo L, Papas MA, Cotugno N, Baker S, Mahoney L, Trabulsi J.

Complementary and alternative medicine use and nutrient intake among individuals with multiple sclerosis in the United States. *J Community Health* 2015;40(1):153–60. Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. **Progressive**

multiple sclerosis: prospects for disease therapy, repair, and restoration of function. *Lancet* 2016. pii: S0140-6736(16)31320-4. doi:10.1016/S0140-6736(16)31320-4. Schuh C, Wimmer I, Hametner S, Haider L, Van Dam AM, Liblau RS, et al. **Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models.** *Acta Neuropathol* 2014;128(2):247–66.

WHO and Multiple Sclerosis International Federation. Atlas: multiple sclerosis resources in the world 2008. Geneva, Switzerland: World Health Organisation Thompson AJ.

Multiple sclerosis— a global disorder and still poorly managed. *Lancet Neurol* 2008;7(12):1078–9. Swank RL, Lestad O, Strøm A, Backer J. **Multiple sclerosis in rural Norway; its geographic and occupational incidence in relation to nutrition.** *N Engl J Med* 1952;246:721–8. Agranoff BW, Golberg D.

Diet and the geographical distribution of multiple sclerosis. *Lancet* 1974;304:1061–6. Alter M, Yamoore M, Harshe M.

Multiple sclerosis and nutrition. *Arch Neurol* 1974;31:267–72. Lauer K. **The risk of multiple sclerosis in the USA in relation to sociogeographic features: a factor-analytic study.** *J Clin Epidemiol* 1994;47:43–8. Esparza ML, Sasaki S, Kesteloot H.

Nutrition latitude and multiple sclerosis mortality: an ecologic study. *Am J Epidemiol* 1995;142:733–7. Antonovsky A, Leibowitz U, Smith HA, Medalie JM, Balogh M, Kats R, et al.

Epidemiologic study of multiple sclerosis in Israel. I. An overall review of methods and findings. Arch Neurol 1965;13:183–93. Cendrowski W, Wender M, Dominik W, Flejsierowicz Z, Owsianowski M, Popiel M. **Epidemiological study of multiple sclerosis in western Poland.** Eur Neurol 1969;2:90–108. Berr C, Puel J, Clanet M, Ruidavets JB, Mas JL, Alperovitch A.

Risk factor in multiple sclerosis: a population-based case control study in Hautes-Pyrenees, France. Acta Neurol Scand 1989;80:46–50. Tola MR, Granieri E, Malagù S, Caniatti L, Casetta I, Govoni V, et al.

Dietary habits and multiple sclerosis. A retrospective study in Ferrara, Italy. Acta Neurol (Napoli) 1994;16:189–97. Zhang SM, Willett WC, Hernán MA, Olek MJ, Ascherio A.

Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. Am J Epidemiol 2000;152:1056–64. Sepčić J, Mesáros E, Materljan E, Sepčić-Grahovac D. **Nutritional factors and multiple sclerosis in Gorski Kotar, Croatia.** Neuroepidemiology 2004;12(4):234–40. Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R.

Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol 1998;27:845–52. Lauer K. Diet and multiple sclerosis. Neurology 1997;49: S55–61. 2017 Esposito et al. **The role of diet in multiple sclerosis: a review.** Harbige LS.

Dietary n-6 and n-3 fatty acids in immunity and autoimmune disease. Proc Nutr Soc 1998;57(4):555–62. Simopoulos AP. **Autoimmune diseases Omega-3 fatty acids in inflammation and.** J Am Coll Nutr 2002;21(6):495–505. Choi IY, Piccio L, Childress P, Bollman B, Ghosh A, Brandhorst S, et al.

A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms. Cell Rep. 2016;15(10):2136–46. Dworkin RH, Bates D, Millar JH, Paty DW.

Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials. Neurology 1984;34:1441–5. Bates D, Cartledge NE, French JM, Jackson MJ, Nightingale S, Shaw DA, et al.

A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 1989;52(1):18–22. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al.

Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids 2005;73(5):397–404. Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, et al.

Omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol 2012;69(8):1044–51. Pantzaris MC, Loukaides GN, Ntzani EE, Patrikios IS.

A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial. BMJ Open. 2013;3(4). pii: e002170. Matarese G, Di Giacomo A, Sanna V, Lord GM, Howard JK, Di Tuoro A, et al.

Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 2001;166(10):5909–16. Sanna V, Di Giacomo A, La Cava A, Lechler RI, Fontana S, Zappacosta S, et al.

Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003;111(2):241–50. Matarese G, La Cava A, Sanna V, Lord GM, Lechler RI, Fontana S, et al.

Balancing susceptibility to infection and autoimmunity: a role for leptin? Trends Immunol. 2002;23(4):182–7. Matarese G, Carrieri PB, La Cava A, Perna F, Sanna V, De Rosa V, et al.

Leptin increase in multiple sclerosis associates with reduced number of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2005;102(14):5150–5. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al.

Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine (metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002;110(8):1093–103. Hårlé P, Straub RH.

Leptin is a link between adipose tissue and inflammation. Ann N Y Acad Sci 2006;1069:454–62. DiPaolo RJ, Glass DD, Bijwaard KE, Shevach EM. **CD4+ CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells.** J Immunol 2005;175(11):7135–42. Frisullo G, Mirabella M, Angelucci F, Caggiula M, Morosetti R, Sancricca C, et al.

The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007;192(1–2):174–83. Matarese G, Procaccini C, De Rosa V.

The intricate interface between immune and metabolic regulation: a role for leptin in the pathogenesis of multiple sclerosis? J Leukoc Biol 2008;84(4):893–9. McGuire C, Prinz M, Beyaert R, van Loo G.

Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology. Trends Mol Med 2013;19(10):604–13. Riccio P, Rossano R, Liuzzi GM. **May diet and dietary supplements improve the wellness of multiple sclerosis patients?** A molecular approach. Autoimmune Dis. 2011;2010:249842. Alatab S, Maghbooli Z, Hossein-Nezhad A, Khosrofar M, Mokhtari F.

Cytokine profile, Foxp3 and nuclear factor-κB ligand levels in multiple sclerosis subtypes. Minerva Med

2011;102(6):461–8. Stelmasiak Z1, Koziol-Montewka M, Dobosz B, Rejdak K, Bartosik-Psujek H, Mitosek-Szewczyk K, et al. **Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients.** *Med Sci Monit* 2000;6(6):1104–8. Trentini A, Manfrinato MC, Castellazzi M, Tamborino C, Roversi G, Volta CA, et al. **TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis.** *Mult Scler* 2015;21(9):1121–30. Mattsson N, Yaong M, Rosengren L, Blennow K, Månsson JE, Andersen O, et al. **Elevated cerebrospinal fluid levels of postal glandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis.** *J Intern Med* 2009;265(4):459–64. Neu IS, Metzger G, Zschocke J, Zelezny R, Mayatepek E. **Leukotrienes in patients with clinically active multiple sclerosis.** *Acta Neurol Scand* 2002;105(1):63–6. Pall ML, Levine S. **Nrf2, a master regulator of detoxification and also antioxidant, anti-inflammatory and other cytoprotective mechanisms, is raised by health promoting factors.** *Sheng Li Xue Bao* 2015;67(1):1–18. Buelna-Chontal M, Zazueta C. **Redox activation of Nrf2 and NF-κB: a double end sword?** *Cell Signal* 2013;25(12):2548–57. Pedruzzi LM, Stockler-Pinto MB, Leite M Jr, Mafrá D. **Nrf2-Keap1 system versus NF-κB: the good and the evil in chronic kidney disease?** *Biochimie* 2012;94(12):2461–6. Kim J, Cha YN, Surh YJ. **A protective role of nuclear factor erythroid 2-related factor-2 (Nrf2) in inflammatory disorders.** *Mutat Res* 2010;690:12–23. Becker J, Delayre-Orthez C, Frossard N, Pons F. **Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?** *Fundam Clin Pharmacol* 2006;20:429–47. Wang K, Wan YJ. **Nuclear receptors and inflammatory diseases.** *Exp Biol Med (Maywood)*. 2008;233(5):496–506. Riccio P, Rossano R. **Nutrition facts in multiple sclerosis.** *ASN Neuro*. 2015;7(1). pii: S0140-6736(16)31320-4. doi:10.1177/1759091414568185. Hooper LV, Midtvedt T, Gordon JI. **How host-microbial interactions shape the nutrient environment of the mammalian intestine.** *Annu Rev Nutr* 2002;22:283–307. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. **The gut microbiota as an environmental factor that regulates fat storage.** *Proc Natl Acad Sci U S A*. 2004;101(44):15718–23. Bouskra D, Brézillon C, Bérard M, Werts C, Varona R, Boneca IG, et al. **Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis.** *Nature* 2008;456(7221):50710. Belkaid Y, Hand TW. **Role of the microbiota in immunity and inflammation.** *Cell* 2014;157(1):121–41. 58 Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. **The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice.** *Sci Transl Med* 2009;1:6ra14–. Panda S, Guarnier F, Manichanh C. **Structure and functions of the gut microbiome.** *Endocr Metab Immune Disord Drug Targets* 2014;14(4):290–9. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. **Linking long-term dietary patterns with gut microbial enterotypes.** *Science* 2011;334(6052):105–8. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. **Diet rapidly and reproducibly alters the human gut microbiome.** *Nature* 2013;505(7484): 559–63. Brown K, DeCoffe D, Molcan E, Gibson DL. **Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease.** *Nutrients* 2012;4(8):1095–119. Guinane CM, Cotter PD. **Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ.** *Therap Adv Gastroenterol* 2013;6(4): 295–308. Cavalcante-Silva LH, Galvão JG, da Silva JS, de Sales-Neto JM, Rodrigues-Mascarenhas S. **Obesity-driven gut microbiota inflammatory pathways to metabolic syndrome.** *Front Physiol* 2015;6:782. Mielcarz DW, Kasper LH. **The gut microbiome in multiple sclerosis.** *Curr Treat Options Neurol* 2015;17(4):938. Eisenstein EM, Williams CB. **The T(reg)/Th17 cell balance: a new paradigm for autoimmunity.** *Pediatr Res* 2009;65(5 Pt 2): 26R–Lochner M, Wang Z, Sparwasser T. **The special relationship in the development and function of T helper 17 and regulatory T cells.** *Prog Mol Biol Transl Sci* 2015;136:99–129. Maynard CL, Elson CO, Hatton RD, Weaver CT. **Reciprocal interactions of the intestinal microbiota and immune system.** *Nature* 2012;489(7415):231–41. Nutritional Neuroscience 11 2017 Esposito et al. **The role of diet in multiple sclerosis: a review.** Kanauchi O, Serizawa I, Araki Y, Suzuki A, Andoh A, Fujiyama Y, et al. **Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment.** *J Gastroenterol* 2003;38(2): 134–41. Brahe LK, Astrup A, Larsen LH. **Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases?** *Obes Rev* 2013;14(12):950–9. Jhangei S, Gandhi R, Glanz B, Cook S, Nejad P, Ward D, et al. **Increased archaea species and changes with therapy in gut microbiome of multiple sclerosis subjects (S24.001).** *Neurology*, 2014;82(10 Suppl):S24. 001–S024. 001. Bhargava P, Mowry EM. **Gut microbiome and multiple sclerosis.** *Curr Neurol Neurosci Rep* 2014;14:240. Tremlett H, Fadrosch D, Lynch S, Hart J, Graves J, Lulu S, et al.

Gut microbiome in early pediatric multiple sclerosis: a case control study [Abstract]. *Neurology* 2015;84:14 Supplement P4.027 Mowry E, Waubant E, Chehoud C, DeSantis T, Kuczynski J, Warrington J.

Gut bacterial populations in multiple sclerosis and in health (P05.106). *Neurology* 2012;78:P05.106 Joscelyn J, Kasper LH. **Digesting the emerging role for the gut microbiome in central nervous system demyelination**. *Mult Scler* 2014;20(12):1553–9 Clemente-Postigo M, Queipo-Ortuño MI, Murri M, Boto Ordoñez M, Perez-Martinez P, Andres-Lacueva C, et al.

Endotoxin increase after fat overload is related to postprandial hypertriglyceridemia in morbidly obese patients. *J Lipid Res* 2012;53(5):973–8. Erridge C, Attina T, Spickett CM, Webb DJ.

A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. *Am. J. Clin. Nutr* 2007;86(5): 1286–92. Laugerette F, Vors C, Géoën A, Chauvin MA, Soulage C, Lambert-Porcheron S, et al.

Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. *J Nutr Biochem* 2011;22(1):53–9. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC, et al.

Energy intake is associated with endotoxemia in apparently healthy men. *Am J Clin Nutr* 2008;87(5): 1219–23.

Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. **Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia**. *Diabetologia* 2007;50: 2374–83. Hotamisligil GS.

Inflammation and metabolic disorders. *Nature* 2006;444(7121):860–7. Nanri A, Moore MA, Kono S. **Impact of C-reactive protein on disease risk and its relation to dietary factors**. *Asian Pac J Cancer Prev* 2007;8(2):167–77. Pereira SS, Alvarez-Leite JL.

Low-grade inflammation, obesity, and diabetes. *Curr Obes Rep* 2014;3(4):422–31. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: **prospective results from the Bruneck Study**. *J Am Coll Cardiol* 1999;34:1975–Witjes JJ, van Raalte DH, Nieuwdorp M.

About the gut microbiome as a pharmacological target in atherosclerosis. *Eur J Pharmacol* 2015;763(PtA):75–8. Nagpal R, Kumar M, Yadav AK, Hemalatha R, Yadav H, Marotta F, et al.

Gut microbiota in health and disease: an overview focused on metabolic inflammation. *Benef Microbes* 2016;7(2):181–94. Chassaing B, Gewirtz AT.

Gut microbiota, low-grade inflammation, and metabolic syndrome. *Toxicol Pathol* 2014;42(1): 49–Aronson KJ, Cleghorn G, Goldenberg E. Assistance arrangements and use of services among persons with multiple sclerosis and their caregivers. *Disabil Rehabil* 1996;18(7): 354–61. Payne A.

Nutrition and diet in the clinical management of multiple sclerosis. *J Hum Nutr Diet* 2001;14(5):349–

57. Guan XL, Wang H, Huang HS, Meng L. **Prevalence of dysphagia in multiple sclerosis: a systematic review and meta-analysis**. *Neurol Sci* 2015;36(5):671–81. Timmerman GM, Stuifbergen AK.

Eating patterns in women with multiple sclerosis. *J Neurosci Nurs* 1999;31(3):152–8. 12 Nutritional

Neuroscience Hadgkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, van der Meer DM. **The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis**. *Nutr Neurosci* 2015;18(3):125–36. Malosse D, Perron H, Sasco A, Seigneurin JM.

Correlation between milk and dairy product consumption and multiple sclerosis prevalence: a worldwide study.

Neuroepidemiology 2004;11(4–6):304–12. Pekmezovic TD, Tepavcevic DBK, Mesáros ST, Basuroski IBD, Stojavljevic NS, Drulovic JS, et al.

Food and dietary patterns and multiple sclerosis: a case-control study in Belgrade (Serbia). *Italian Journal of Public Health* 2009;6:81–7. Hadgkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, van der Meer DM.

Methodology of an international study of people with multiple sclerosis recruited through Web 2.0 platforms: demographics, lifestyle, and disease characteristics. *Neurol Res Int* 2013;2013:580596.

KesVB, Cesarik M, Matovina LZ, Zavoreol, Corić L, Drnasin S, et al. **The role of complementary and alternative medicine in therapy of multiple sclerosis**. *Acta Clin Croat* 2013;52(4): 464–71. Leong EM, Semple SJ, Angley M, Siebert W, Petkov J, McKinnon RA.

Complementary and alternative medicines and dietary interventions in multiple sclerosis: what is being used in South Australia and why? *Complement Ther Med* 2009;17(4):216–23. Swank RL.

Treatment of multiple sclerosis with a low-fat diet. *J Am Diet Assoc* 1960;36:322–5. Swank RL, Dugan BB. **Effect of low saturated fat diet in early and late cases of multiple sclerosis**. *Lancet* 1990;336:37–9. Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G.

Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev 2012;12:CD004192. Schwarz S, Leweling H.
Multiple sclerosis and nutrition. Mult Scler 2005;11(1):24–32. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T.

High frequency of adverse health behaviors in multiple sclerosis. Mult Scler 2009;15(1):105–13. Pinhas-Hamiel O, Livne M, Harari G, Achiron A.
Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability. Eur J Neurol 2015;22(9):1275–9. Ranadive SM, Yan H, Weikert M, Lane AD, Linden MA, Baynard T, et al.

Vascular dysfunction and physical activity in multiple sclerosis. Med Sci Sports Exerc 2012;44(2):238–43. Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, et al.

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler 2015;21(3):318–31. Tettey P, Simpson S Jr, Taylor BV, van der Mei IA.
Vascular comorbidities in the onset and progression of multiple sclerosis. J Neurol Sci 2014;347(1–2):23–33. Ge KY, Chang SY.
Definition and measurement of child malnutrition. Biomed Environ Sci 2001;14(4):283–91. Sorgun MH, Yucesan C, Tegin C.
Is malnutrition a problem for multiple sclerosis patients? J Clin Neurosci 2014;21(9): 1603–5. Williams CM, Lines CM, McKay EC.

Iron and zinc status in multiple sclerosis patients with pressure sores. Eur J Clin Nutr 1988;42(4):321–8. Slawta JN, Wilcox AR, McCubbin JA, Nalle DJ, Fox SD, Anderson G.
Health behaviors, body composition, and coronary heart disease risk in women with multiple sclerosis. Arch Phys Med Rehabil 2003;84(12):1823–30. Williams AE, Vietri JT, Isherwood G, Flor A.
Symptoms and association with health outcomes in relapsing-remitting multiple sclerosis: results of a US patient survey. Mult Scler Int 2014;2014:203183. 112 Motl RW, McAuley E, Snook EM. Physical activity and multiple sclerosis: a meta-analysis. Mult Scler 2005;11(4):459–63. Fogelholm M.

Physical activity, fitness and fatness: relations to mortality, morbidity and disease risk factors. A systematic review. Obes Rev 2010;11(3):202–21. Jick SS, Li L, Falcone GJ, Vassilev ZP, Wallander MA.

Mortality of patients with multiple sclerosis: a cohort study in UK primary care. J Neurol 2014;261(8):1508–17. Wens I, Dalgas U, Stenager E, Eijnde BO.
Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis— a systematic review. Mult Scler 2013;19(12): 1556–64. 2017 Eposito et al. The role of diet in multiple sclerosis: a review Monzani A, Rapa A, Prodam F, Fuiano N, Diddi G, Petri A, et al.

High discrepancy in abdominal obesity prevalence according to different waist circumference cut-offs and measurement methods in children: need for age-risk-weighted standardized cut-offs? PLoS One 2016;11(1):e0146579. Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, et al.

Body mass index, abdominal fatness and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation 2016;133(7): 6Marrie RA, Elliott L, Marriott J, Cossoy M, Blanchard J, Tennakoon A, et al.
Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology 2014;83(10):929–37. Montalcini T, Moraca M, Ferro Y, Romeo S, Serra S, Raso MG, et al.

Nutritional parameters predicting pressure ulcers and short-term mortality in patients with minimal conscious state as a result of traumatic and non-traumatic acquired brain injury. J Transl Med 2015;13:345. Cereda E, Klersy C, Andreola M, Pisati R, Schols JM, Caccialanza R, et al.; OligoElement Sore Trial (OEST) Study Group.
Cost-effectiveness of a disease-specific oral nutritional support for pressure ulcer healing. Clin Nutr. 2017;36(1):246–52. Demarré L, Van Lancker A, Van Hecke A, Verhaeghe S, Grypdonck M, Lemey J, et al.

The cost of prevention and treatment of pressure ulcers: a systematic review. Int J Nurs Stud 2015;52(11):1754–74. 122 Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008;22:671–85. Gupta S, Ahsan I, Mahfooz N, Abdelhamid N, Ramanathan M, Weinstock-Guttman B.

Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. CNS Drugs 2014;28(8):731–42. Peters BS, Verly E Jr, Marchioni DM, Fisberg M, Martini LA.

The influence of breakfast and dairy products on dietary calcium and vitamin D intake in postpubertal adolescents and young adults. J Hum Nutr Diet 2012;25(1):69–74. Dobson R, Ramagopalan S, Giovannoni G.

Bone health and multiple sclerosis. Mult Scler 2012;18(11):1522–8. Dong G, Zhang N, Wu Z, Liu Y, Wang L. Multiple sclerosis increases fracture risk: a meta-analysis. Biomed Res Int 2015;2015:650138. Wiesel PH, Norton C, Glickman S, Kamm MA.

Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol 2001;13(4):441–8. Preziosi G, Emmanuel A.

Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and treatment. Expert Rev Gastroenterol Hepatol 2009;3(4):417–23. Coggrave M, Norton C, Cody JD.

Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database Syst Rev 2014;(1):CD002115. Corcos J.

A urological challenge: voiding dysfunction in multiple sclerosis. Can Urol Assoc J 2013;7(9–10 Suppl 4):181–2. Kaplan SA, Dmochowski R, Cash BD, Kopp ZS, Berriman SJ, Khullar V.

Systematic review of the relationship between bladder and bowel function: implications for patient management. Int J Clin Pract 2013;67(3):205–16. Roman Łczuk W, Korczawski R.

Chronic constipation: a cause of recurrent urinary tract infections. Turk J Pediatr 1993;35(3): 181– Hellerstein S, Linebarger JS. Voiding dysfunction in pediatric patients. Clin Pediatr (Phila). 2003;42(1):43–9. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, et al.

Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125(Pt 5):952–60. Schwenger EM, Tejani AM, Loewen PS.

Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev 2015;12:CD008772. Jepson RG, Williams G, Craig JC. **Cranberries for preventing urinary tract infections.** Cochrane Database Syst Rev 2012;10: CD00Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, et al. What is subjective global assessment of nutritional status? J Parenter Enteral Nutr 1987;11:8. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M;

Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN). ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003;22(4):415–21. Rubenstein LZ, Harker JO, Salvà A, Guigoz Y, Vellas B. **Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF).** J Gerontol A Biol Sci Med Sci 2001;56(6):M366–72. Guigoz Y.

The Mini Nutritional Assessment (MNA) review of the literature– What does it tell us? J Nutr Health Aging 2006;10(6):466–85. British Association for Enteral and Parenteral Nutrition (BAPEN). The ‘MUST’ explanatory booklet.

A guide to ‘Malnutrition Universal Screening Tool’ (‘MUST’) for adults; [cited Nov 2003]. Pasquinelli S, Solaro C.

Nutritional assessment and malnutrition in multiple sclerosis. Neurol Sci 2008;29(Suppl 4):367–9. Lee SY, Gallagher D.

Assessment methods in human body composition. Curr Opin Clin Nutr Metab Care 2008;11(5): 566–72. Wöndin K, Ekman S, Bülow M, Ekberg O, Johansson D, Rothenberg E, et al.

Objective and quantitative definitions of modified food textures based on sensory and rheological methodology. Food Nutr Res 2010;54:5134–44. Parsons EL, Stratton RJ, Cawood AL, Smith TR, Elia M.

Oral nutritional supplements in a randomised trial are more effective than dietary advice at improving quality of life in malnourished care home residents. Clin Nutr 2016;36(1):134–42. Scott R, Bowling TE. Enteral tube feeding in adults. J R Coll Physicians Edinb 2015;45(1):49–54. Zalar AE, Guédon C, Piskorz EL, Sánchez Basso A, Ducrotté P.

Percutaneous endoscopic gastrostomy in patients with neurological diseases. Results of a prospective multicenter and international study. Acta Gastroenterol Latinoam 2004;34(3): 127–3. Bourre JM. **Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing.** J Nutr Health Aging 2004;8(3):163–74. WHO, FAO.

Fats and fatty acids in human nutrition report of an expert consultation. Rome: Food and Agriculture organization of the United Nations; 2010. Gallai V, Sarchielli P, Trequattrini A, Franceschini M, Floridi A, Firenze C, et al.

Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol 1995;56(2):143–53. de Jong

AJ, Kloppenburg M, Toes RE, Ioan-Facsinay A. **Fatty acids, lipid mediators, and T-cell function.** Front Immunol

2014;5:483. 152 Simopoulos AP. **The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases.** Exp Biol Med (Maywood) 2008;233(6):674–88. Schmitz G, Ecker J. **The opposing effects of n-3 and n-6 fatty acids.** Prog Lipid Res 2008;47(2):14755. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, et al.

Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004;292:1440–6. Fedor D, Kelley DS. **Prevention of insulin resistance by n-3 polyunsaturated fatty acids.** Curr Opin Clin Nutr Metab Care 2009;12:138–46. Gupta R, Lakshmy R, Abraham RA, Reddy KS, Jeemon P, Prabhakaran D, et al.

Serum omega-6/omega-3 ratio and risk markers for cardiovascular disease in an industrial population of Delhi. Food Nutr Sci 2013;4:94–7. Riccio P, Rossano R, Larocca M, Trotta V, Mennella I, Vitaglione P, et al.

Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: a pilot study. Exp Biol Med (Maywood). 2016;241(6):620–Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, et al.

The nonskeletal effects of vitamin D: an endocrine society scientific statement. *Endocr Rev* 2012;33(3): 456–92 Hayes CE, Nashold FE, Spach KM, Pedersen LB.

The immunological functions of the vitamin D endocrine system. *Cell Mol Biol (Noisy-le grand)* 2003;49(2):277–300. Nutritional Neuroscience 13 2017 Esposito et al. The role of diet in multiple sclerosis: a review 160 Besusso D, Saul L, Leech MD, O'Connor RA, MacDonald AS, Anderton SM, et al. 1,25-Dihydroxyvitamin D3-conditioned CD11c+ dendritic cells are effective initiators of CNS autoimmune disease. *Front Immunol* 2015;6:233. Lucas RM, Byrne SN, Correale J, Illesch S, Hart PH.

Ultraviolet radiation, vitamin D and multiple sclerosis. *Neurodegener Dis Manag* 2015;5(5):413–24. Farinotti M, Simi S, Di Pietrantonj C, McDowell N, Brait L, Lupo D, et al. **Dietary interventions for multiple sclerosis.** *Cochrane Database Syst Rev* 2007;(1):CD004192. Hussain AN, Alkhenizan AH, El Shaker M, Raef H, Gabr A. Increasing trends and significance of hypovitaminosis D: a population-based study in the Kingdom of Saudi Arabia. *Arch Osteoporos* 2014;9:6. Adami S, Romagnoli E, Carnevale V, Scillitani A, Giusti A, Rossini M, et al. **Guidelines on prevention and treatment of vitamin D deficiency.** *Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases* *Reumatismo* 2011;63(3):129– Institute of Medicine (US) Standing Committee on the **Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline.** Washington (DC): National Academies Press (US); 1998 Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. *Br Med Bull* 1999;55(3):669–82. Zhu Y, He ZY, Liu HN. **Meta-analysis of the relationship between homocysteine, vitamin B12, folate, and multiple sclerosis.** *J Clin Neurosci* 2011;18(7):933–8. Najafi MR, Shaygannajad V, Mirpourian M, Gholamrezaei A. **Vitamin B(12) deficiency and multiple sclerosis; is there any association?** *Int J Prev Med* 2012;3(4):286–9. Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, et al. **High doses of biotin in chronic progressive multiple sclerosis: a pilot study.** *Mult Scler Relat Disord* 2015;4 (2):159–69. Peyro Saint Paul L, Debruyne D, Bernard D, Mock DM, Defer GL.

Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. *Expert Opin Drug Metab Toxicol* 2016;12(3): 327–44. Institute of Medicine, **Food and Nutrition Board. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc.** Washington, DC: National Academy Press; 2001. WHO. Global prevalence of vitamin A deficiency in populations at risk 1995–2005. **WHO global database on vitamin A deficiency.** Geneva: World Health Organization; 2009. Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS, et al. **Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course.** *J Immunol.* 1995;154:450. 14 Nutritional Neuroscience Sheng X, Hulin J, Thomas K, Sue ML, Mohamed O, Bing L, et al. **Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF- β -driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression.** *J Immunol.* 2008;181(4):2455–64. Bitarafan S, Saboor-Yaraghi A, Sahraian MA, Soltani D, Nafissi S, Togha M, et al. **Effect of vitamin A supplementation on fatigue and depression in multiple sclerosis patients: a double-blind placebo-controlled clinical trial.** *Iran J Allergy Asthma Immunol.* 2016;15(1):13–9. Yasui M, Yase Y, Ando K, Adachi K, Mukoyama M, Ohsugi K. **Magnesium concentration in brains from multiple sclerosis patients.** *Acta Neurol Scand* 1990;81(3):197–200. Johnson S. **The possible role of gradual accumulation of copper, cadmium, lead and iron and gradual depletion of zinc, magnesium, selenium, vitamins B2, B6, D, and E and essential fatty acids in multiple sclerosis.** *Med Hypotheses* 2000;55(3):239–Haider L, Simeonidou C, Steinberger G, Hametner S, Grigoriadis N, Deretzi G, et al. **Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron.** *J Neurol Neurosurg Psychiatry* 2014;85 (12):1386–Bitarafan S, Harirchian MH, Nafissi S, Sahraian MA, Togha M, Siassi F, et al. **Dietary intake of nutrients and its correlation with fatigue in multiple sclerosis patients.** *Iran J Neurol* 2014;13 (1):28–32. Prasad AS. Impact of the discovery of human zinc deficiency on health. *J Trace Elem Med Biol* 2014;28(4):357–63. de Baaij JH, Hoenderop JG, Bindels RJ. **Magnesium in man: implications for health and disease.** *Physiol Rev* 2015;95(1):1–46. Solov'yev ND. **Importance of selenium and selenoprotein for brain function: from antioxidant protection to neuronal signaling.** *J Inorg Biochem* 2015;153:1–12. Ramsaransing GS, Mellema SA, De Keyser J. **Dietary patterns in clinical subtypes of multiple sclerosis: an exploratory study.** *Nutr J* 2009;8:345. Combs GF Jr. **Selenium in global food systems.** *Br J Nutr* 2001;85(5):517–47. Volpe S.L. **Magnesium in disease prevention and overall health.** *Adv Nutr* 2013;4(3):378S–83S. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, et al. **Oxidative damage in multiple sclerosis lesions.** *Brain* 2011;134(Pt7):1914–24. Hadžović-Džuvo A, Lepara O, Valjevac A, Avdagić N, Hasić S, Kiseljaković E, et al. **Serum total antioxidant capacity in patients with multiple sclerosis.** *Bosn J Basic Med Sc* 2011;11(1):33–6. Plemel JR, Juzwik CA, Benson CA, Monks M, Harris C, Ploughman M. **Over-the-counter anti-oxidant therapies for use in multiple sclerosis: a systematic review.** *Mult Scler* 2015;21(12):1485–95